7 Contradicted by research
There are more metabolically unhealthy normal-weight individuals in the United States than metabolically unhealthy obese individuals.
"And actually it turns out there are more thin, sick people in America than there are fat, sick people" (said at 0:19:22)
Nationally representative data from the National Health and Nutrition Examination Survey (NHANES) contradict the claim that there are more metabolically unhealthy normal-weight individuals ("thin, sick") in the United States than metabolically unhealthy obese individuals ("fat, sick"). An analysis of NHANES data from 1999 to 2018 (PMID: 35691704) found that the prevalence of metabolically unhealthy normal weight was 2.10% (declining from 3.77% in 1999), compared to a prevalence of 26.4% for metabolically unhealthy obesity (increasing from 19.0% in 1999). Even when looking at broader definitions or proportions within BMI categories (PMID: 26841729), approximately 30% of normal-weight US adults are cardiometabolically unhealthy compared to about 71% of obese adults (and 84% of class II/III obese adults), resulting in a substantially larger absolute and relative population of metabolically unhealthy individuals in the overweight and obese categories compared to the normal-weight category.
- contradicts: Misclassification of cardiometabolic health when using body mass index categories in NHANE… (International journal of obesity (2005) 2016) · cited 346x in the literature
"Nearly half of overweight individuals, 29% of obese individuals and even 16% of obesity type 2/3 individuals were metabolically healthy. Moreover, over 30% of normal weight individuals were cardiometabolically unhealthy." (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: Trends in Metabolic Phenotypes According to Body Mass Index Among US Adults, 1999-2018. (Mayo Clinic proceedings 2022) · cited 22x in the literature
"The prevalence declined from 3.77% (72 of 1646) to 2.10% (68 of 2058) (difference, -1.67%; 95% CI, -3.22% to -0.12%; P=.006 for trend) for metabolically unhealthy normal weight, whereas it increased from 19.0% (343 of 1646) to 26.4% (574 of 2058) (difference, 7.41%; 95% CI, 2.67% to 12.2%; P<.001 for trend) for MU-OB." (abstract, results, passage verified)
pubmedfull study (doi)
Exercise does not reduce glycation and actually makes glycation worse.
"So it does not affect glycation; it actually makes glycation worse." (said at 0:35:54)
The claim that exercise does not reduce glycation and actually worsens it is directly contradicted by clinical trial and epidemiological evidence. Large meta-analyses of hundreds of randomized controlled trials show that exercise training consistently lowers glycated hemoglobin (HbA1c), a primary biomarker of protein glycation. Furthermore, a systematic review investigating the accumulation of advanced glycation end products (AGEs, measured via skin autofluorescence) found that higher physical activity and exercise levels are inversely associated with tissue glycation, with no studies finding that physical activity increases or worsens glycation accumulation.
- contradicts: The effect of exercise characteristics on HbA1c and other cardiovascular risk factors in a… (Cardiovascular diabetology 2025) · cited 12x in the literature
"All exercise types significantly improved HbA1c, with the largest reductions observed for combined training (− 0.74%, 95% CI [− 0.91; − 0.57], n = 38) and high-intensity interval training (HIIT) (− 0.71%, 95% CI [− 1.07; − 0.35], n = 13), followed by continuous aerobic training (CAT) (− .62%, 95% CI [− 0.84; − 0.41], n = 57) and resistance training (− 0.36%, 95% CI [− 0.51; − 0.20], n = 38)." (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: Analysis of the potential association between physical activity and skin autofluorescence:… (Journal of epidemiology and community health 2026) · cited 1x in the literature
"Specifically, 58.8% of the studies reported a statistically significant inverse association, indicating that higher levels of PA or exercise frequency are correlated with lower SAF levels. The remaining studies (41.2%) reported non-significant results, though several showed favourable trends. No studies reported a positive association between PA and SAF." (abstract, results, passage verified)
pubmedfull study (doi)
Exercise does not reduce oxidative stress and actually makes oxidative stress worse.
"It does not affect oxidative stress; exercise actually makes oxidative stress worse." (said at 0:35:59)
The claim that exercise does not reduce oxidative stress and only worsens it is contradicted by systematic reviews and meta-analyses of randomized controlled trials. While a single, acute bout of strenuous exercise causes a transient increase in reactive oxygen species and oxidative stress biomarkers (such as protein carbonyls and F2-isoprostanes), regular exercise training induces adaptative increases in endogenous antioxidant enzymes (such as superoxide dismutase) and causes a net reduction in basal pro-oxidants and lipid peroxidation markers (such as malondialdehyde).
- contradicts: Effect of exercise intensity on redox biomarkers in healthy adults: A systematic review an… (PloS one 2025) · cited 3x in the literature
"Individual evaluations demonstrated an increase in antioxidant capacity (I2=0%, Z=4.56, p<0.00001) and superoxide dismutase (I2=52%, Z=1.94, p=0.05), an antioxidant enzyme, and decrease in pro-oxidant (I2=0%, Z=5.91, p<0.0001); there was no significant difference in glutathione peroxidase (I2=81%, Z=0.50, p=0.62). The effect of vigorous interventions showed an increase in antioxidants (Z=2.44, I2=67%, p=0.01) and a decrease in oxidants (Z=5.44, I2=0%, p<0.00001)" (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: The effects of exercise on oxidative stress MDA and SOD in patients with type 2 diabetes: … (PeerJ 2025) · cited 5x in the literature
"The results of the meta-analysis showed that exercise can improve malondialdehyde (MDA), standardized mean difference (SMD) = -1.29, 95% CI [-1.87 to -0.71], P < 0.0001 in patients with T2DM; and improve superoxide dismutase (SOD), SMD = 0.59, 95% CI [0.17-1.01], P = 0.006 in patients with T2DM." (abstract, results, passage verified)
pubmedfull study (doi) - context: Optimal timing to assess exercise-induced oxidative stress: A systematic review and meta-a… (Experimental physiology 2025) · cited 2x in the literature
"Glutathione levels decreased immediately (g = -0.70; 95% CI: -0.96, -0.44; P < 0.001), at 30 min to 2 h (g = -0.81; 95% CI: -1.19, -0.43; P < 0.001), and 48 h post-exercise (g = -0.98; 95% CI: -1.50, -0.46; P < 0.01). F 2 -isoprostanes increased immediately post-exercise (g = 1.01; 95% CI: 0.70, 1.33; P < 0.001) and at 30 min to 2 h (g = 0.46; 95% CI: 0.23, 0.69; P < 0.001)." (abstract, results, passage verified)
pubmedfull study (doi)
African Americans accumulate less hepatic fat on average due to a mutation in the APOC3 gene.
"In African Americans, it should be 20 for that matter because they actually don't even make as much fat in the liver. They have a mutation in their APOC3 gene, so they actually don't accumulate as much fat." (said at 0:53:12)
The claim that African Americans accumulate less hepatic fat due to a mutation in the APOC3 gene is contradicted by population-based genetics studies examining APOC3 variants, hepatic triglyceride content (HTGC), and ethnicity. In a large multiethnic cohort study (the Dallas Heart Study, n=1,228 African Americans), candidate APOC3 gene variants (rs2854117 and rs2854116) showed no significant difference in hepatic fat content between carriers and noncarriers, refuting the proposed role of APOC3 variants in driving lower hepatic fat accumulation in African Americans (PMID: 21274868). Similarly, in obese pediatric cohorts evaluated across racial groups, APOC3 gene variants were not associated with hepatic fat fraction, whereas variants in genes such as PNPLA3 and GCKR were associated with liver fat accumulation across ethnicities (PMID: 22105854).
- contradicts: Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. (Hepatology (Baltimore, Md.) 2011) · cited 114x in the literature
"Here we genotyped two APOC3 variants in 1228 African Americans, 843 European Americans and 426 Hispanics from a multiethnic population based study, the Dallas Heart Study and test for association with HTGC and homeostatic model of insulin resistance (HOMA-IR)... No significant difference in hepatic fat content was found between carriers and noncarriers in the Dallas Heart Study. Neither APOC3 variant was associated with HOMA-IR in the Dallas Heart Study... Our data do not support a causal relationship between these two variants in APOC3 and either HTGC or insulin resistance in middle-aged men and women." (abstract, results and conclusions, passage verified)
pubmedfull study (doi) - contradicts: Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver i… (Hepatology (Baltimore, Md.) 2012) · cited 267x in the literature
"The PNPLA3, but not the APOC3 rs2854116 SNP, was associated with fatty liver but not with triglyceride levels." (abstract, results, passage verified)
pubmedfull study (doi)
Homocysteine is normally metabolized through the urea cycle to succinate by the enzyme methylenetetrahydrofolate reductase (MTHFR).
"And the thing is that homocysteine is normally metabolized down the urea cycle to succinate by the enzyme MTHFR, methylenetetrahydrofolate reductase." (said at 1:01:26)
The speaker fundamentally misstates the biochemistry of homocysteine metabolism. Homocysteine is not metabolized through the urea cycle to succinate by methylenetetrahydrofolate reductase (MTHFR). In human biochemistry, homocysteine has two major pathways: remethylation back to methionine and transsulfuration to cysteine. MTHFR catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which provides the methyl group used by methionine synthase to remethylate homocysteine into methionine. The urea cycle is a distinct pathway responsible for ammonia detoxification, and succinate is an intermediate of the citric acid (TCA) cycle.
- contradicts: Metabolism of homocysteine and its relationship with cardiovascular disease. (Journal of thrombosis and thrombolysis 2004) · cited 59x in the literature
"Methionine regenerates by retrieving the methyl radical from 5-methyltetrahydrofolate (5-MTHF) creating tetrahydrofolate (THF) which will then regenerate to 5-MTHF through the action of methylentetrahydrofolate reductase (MTHFR). This process is called remethylation. Alternatively, Hcy can follow the transsulfuration route, where through cystationine-beta-syntetase (CBS), it irreversibly converted into cystationine, a precursor of cysteine, glutathione, and other substances that are finally excreted in the urine." (abstract, passage verified)
pubmedfull study (doi) - contradicts: Genetics of homocysteine metabolism and associated disorders. (Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 2010) · cited 208x in the literature
"Homocysteine is a sulfur-containing amino acid derived from the metabolism of methionine, an essential amino acid, and is metabolized by one of two pathways: remethylation or transsulfuration." (abstract, passage verified)
pubmedfull study (doi)
ACE2 is normally a water channel in cells, especially in the lungs.
"ACE2, angiotensin-converting enzyme 2. Now, that is normally a water channel in cells, especially lung, but it drives the production of ACE2." (said at 1:07:40)
ACE2 (angiotensin-converting enzyme 2) is not a water channel; it is a membrane-bound zinc carboxypeptidase within the renin-angiotensin system that cleaves angiotensin II into angiotensin-(1-7) and serves as the cellular entry receptor for SARS-CoV and SARS-CoV-2. The cellular proteins that function as water channels are aquaporins (e.g., AQP1 through AQP5), which the speaker may have confused with ACE2 due to the similar abbreviation of Aquaporin-2 (AQP2).
- contradicts: Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partn… (Pharmacology & therapeutics 2010) · cited 504x in the literature
"Angiotensin-converting enzyme (ACE) 2 is a homolog to the carboxypeptidase ACE, which generates angiotensin II, the main active peptide of renin-angiotensin system (RAS). After the cloning of ACE2 in 2000, three major ACE2 functions have been described so far. First ACE2 has emerged as a potent negative regulator of the RAS counterbalancing the multiple functions of ACE." (abstract, background/results, passage verified)
pubmedfull study (doi) - contradicts: Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19. (Frontiers in immunology 2021) · cited 68x in the literature
"ACE2 is a carboxypeptidase which degrades angiotensin II, B1-bradykinin, or apelin, and thereby is a critical regulator of cardiovascular physiology and pathology." (abstract, results, passage verified)
pubmedfull study (doi) - context: Aquaporins in Respiratory System. (Advances in experimental medicine and biology 2023) · cited 5x in the literature
"Aquaporins (AQPs) are water channel proteins facilitating fluid transport in alveolar space, airway humidification, pleural fluid absorption, and submucosal gland secretion. In this chapter, we mainly focus on the expression of four AQPs in the lungs, which include AQP1, AQP2, AQP4, and AQP5 in normal and disease status" (abstract, introduction, passage verified)
pubmedfull study (doi)
High blood glucose crystallizes around ACE2 molecules to keep them open, increasing susceptibility to COVID-19 infection.
"High blood glucose basically crystallizes around the edges of those ACE2 molecules and keeps them open so that the virus has an even easier chance of infecting you." (said at 1:08:40)
The claim mischaracterizes the biochemistry of hyperglycemia and SARS-CoV-2 receptor interaction. Glucose does not physically "crystallize" on cell-surface receptors in aqueous biological fluids. In patients with elevated blood glucose, the actual molecular mechanism involves non-enzymatic glycation (the covalent attachment of glucose molecules to lysine residues) and increased cellular expression of ACE2. Furthermore, in silico structural modeling indicates that glycation of ACE2 residues reduces polar and van der Waals interactions with the viral Spike protein rather than mechanically holding the receptor open.
7 Overstated
Approximately 25% of all children in the United States have non-alcoholic fatty liver disease.
"and in fact 25% of the entire pediatric population of the United States have fatty liver." (said at 0:16:45)
The ~25% prevalence figure comes from recent National Health and Nutrition Examination Survey (NHANES 2017–2020) data evaluating US adolescents (ages 12–19) using transient elastography (controlled attenuation parameter), which identified a non-alcoholic fatty liver disease (NAFLD) prevalence of 25.8% (and metabolic dysfunction-associated steatotic liver disease [MASLD] prevalence of 20–23%). However, applying this figure to the 'entire pediatric population' overstates the prevalence across all childhood ages, as fatty liver disease is significantly less common in younger children, yielding an overall pediatric prevalence estimated at roughly 7% to 10% in general populations.
- context: Recent prevalence and trends of obesity and metabolic dysfunction-associated steatotic liv… (Pediatric obesity 2025) · cited 21x in the literature
"Between 2017 and 2020, the prevalence of obesity and MASLD was approximately 20%, with about 70% of obese adolescents affected by MASLD." (abstract, results, passage verified)
pubmedfull study (doi) - context: MAFLD outperforms NAFLD in identifying metabolic dysfunction in U.S. adolescents: a NHANES… (BMC gastroenterology 2025)
"MAFLD prevalence was 22.8% (95%CI:18.8-26.8) vs. NAFLD's 25.8% (21.5-30.0)." (abstract, results, passage verified)
pubmedfull study (doi) - context: Global and regional prevalence, burden, and risk factors for MASLD in children and adolesc… (BMC medicine 2026) · cited 4x in the literature
"Our model indicated that the global MASLD prevalence among 5-24-year-olds was 7.0% (95% CI: 4.1, 11.7), increasing with age and year, and higher in boys." (abstract, results, passage verified)
pubmedfull study (doi)
Twenty-five percent of children have fatty liver disease when evaluated by MRI.
"and 25% of kids, if you stick them in an MRI scanner, have fatty liver disease." (said at 0:45:03)
Large systematic reviews and meta-analyses show that the prevalence of non-alcoholic fatty liver disease (NAFLD / MASLD) in the general pediatric population is approximately 7% to 14%, not 25%. While hepatic steatosis prevalence reaches 38% to 41% among children with overweight or obesity, and adult global prevalence is approximately 25% to 30%, stating that 25% of children in general have fatty liver disease overstates general pediatric rates.
- contradicts: Global Prevalence of Nonalcoholic Fatty Liver Disease: An Updated Review Meta-Analysis com… (Archives of medical research 2024) · cited 157x in the literature
"The prevalence of NAFLD in adults, adults with obesity, children, and children with obesity was 30.2% (95% CI: 28.8-31.7%), 57.5% (95% CI: 43.6-70.9%), 14.3% (95% CI: 10.3-18.8%), and 38.0% (95% CI: 31.5-44.7%), respectively." (abstract, results, passage verified)
pubmedfull study (doi) - context: Global prevalence of metabolic dysfunction-associated fatty liver disease in children and … (BMC gastroenterology 2025) · cited 19x in the literature
"The global prevalence of MAFLD among children and adolescents with overweight and/or obesity was 41.2% (95% CI 39.7-44.6)." (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: Global and regional prevalence, burden, and risk factors for MASLD in children and adolesc… (BMC medicine 2026) · cited 4x in the literature
"Our model indicated that the global MASLD prevalence among 5-24-year-olds was 7.0% (95% CI: 4.1, 11.7), increasing with age and year, and higher in boys." (abstract, results, passage verified)
pubmedfull study (doi)
Healthcare spending in the United States totals 3.6 trillion dollars annually, with 75% of that spending directed toward chronic metabolic diseases.
"medical care in this country costs 3.6 trillion dollars a year, and of that, 75% are all these chronic metabolic diseases that we've been talking about." (said at 0:42:57)
Official National Health Expenditure Accounts data from the Centers for Medicare & Medicaid Services reported total US healthcare spending at $3.6 trillion in 2018. While public health literature and the CDC frequently estimate that roughly 75% to 90% of US healthcare expenditures are driven by chronic diseases and conditions broadly, attributing this entire 75% share specifically to 'chronic metabolic diseases' is an overstatement. The broad chronic disease category encompasses a wide range of non-metabolic conditions, including musculoskeletal disorders, mental health disorders, cancers, dementia, and chronic respiratory diseases.
- supports: National Health Care Spending In 2018: Growth Driven By Accelerations In Medicare And Priv… (Health affairs (Project Hope) 2020) · cited 179x in the literature
"US health care spending increased 4.6 percent to reach $3.6 trillion in 2018, a faster growth rate than the rate of 4.2 percent in 2017 but the same rate as in 2016." (abstract, results, passage verified)
pubmedfull study (doi) - context: Tracking US Health Care Spending by Health Condition and County. (JAMA 2025) · cited 47x in the literature
"More spending was on type 2 diabetes ($143.9 billion [95% CI, $140 billion-$147.2 billion]) than on any other health condition, followed by other musculoskeletal disorders, which includes joint pain and osteoporosis ($108.6 billion [95% CI, $106.4 billion-$110.3 billion]), oral disorders ($93 billion [95% CI, $92.7 billion-$93.3 billion]), and ischemic heart disease ($80.7 billion [95% CI, $79 billion-$82.4 billion])." (abstract, results, passage verified)
pubmedfull study (doi)
Homocysteine drives cardiovascular smooth muscle proliferation and leads to heart attacks.
"So homocysteine is a driver of cardiovascular smooth muscle proliferation. It is one of the things that leads to heart attacks." (said at 1:01:10)
Preclinical and mechanistic studies confirm that elevated homocysteine promotes vascular smooth muscle cell (VSMC) proliferation, migration, and phenotypic switching in vitro and in animal models. Furthermore, observational epidemiology shows an association between hyperhomocysteinemia and cardiovascular risk. However, the claim that homocysteine directly leads to heart attacks is overstated. High-certainty evidence from large-scale randomized controlled trials and a Cochrane systematic review involving over 46,000 participants shows that lowering plasma homocysteine levels with B-vitamin supplementation (folic acid, B6, and B12) does not reduce the incidence of myocardial infarction (RR 1.02, 95% CI 0.95 to 1.10) or all-cause mortality, indicating that homocysteine is a marker or correlated risk factor rather than an independent causal driver of heart attacks in humans.
- contradicts: Homocysteine-lowering interventions for preventing cardiovascular events. (The Cochrane database of systematic reviews 2017)
"Compared with placebo, there were no differences in effects of homocysteine-lowering interventions on myocardial infarction (homocysteine-lowering = 7.1% versus placebo = 6.0%; RR 1.02, 95% confidence interval (CI) 0.95 to 1.10, I 2 = 0%, 12 trials; N = 46,699; Bayes factor 1.04, high-quality evidence), death from any cause (homocysteine-lowering = 11.7% versus placebo = 12.3%, RR 1.01, 95% CI 0.96 to 1.06, I 2 = 0%, 11 trials, N = 44,817; Bayes factor = 1.05, high-quality evidence)" (abstract, results, passage verified)
pubmedfull study (doi) - supports: Proliferation, migration and phenotypic transformation of VSMC induced via Hcy related to … (PloS one 2024) · cited 6x in the literature
"This study revealed that WWP2 could promote the proliferation, migration, and phenotype switch of Hcy-induced VSMC by up-regulating the phosphorylation of SIRT1/STAT3 signaling." (abstract, results, passage verified)
pubmedfull study (doi) - context: Atherogenic Effect of Homocysteine, a Biomarker of Inflammation and Its Treatment. (The International journal of angiology : official publication of the International College of Angiology, Inc 2024) · cited 12x in the literature
"HHcy-induced atherosclerosis may be mediated through oxidative stress, decreased availability of nitric oxide (NO), increased expression of monocyte chemoattractant protein-1, smooth muscle cell proliferation, increased thrombogenicity, and induction of arterial connective tissue." (abstract, passage verified)
pubmedfull study (doi)
Only 28% of US medical schools have a nutrition curriculum.
"Well, only 28% of medical schools even have a nutrition curriculum, and there's no CMEs for nutrition, except some rare things like integrative medicine at University of Arizona" (said at 1:03:12)
The cited figure appears to conflate national survey findings on medical school nutrition education. In a national survey of accredited U.S. medical schools by Adams et al. (2010), 94.5% (103/109) of responding schools required some form of nutrition education, typically integrated into other courses. However, only 25% (26/105) required a dedicated, standalone nutrition course, and only 27% (28/105) met the National Academy of Sciences recommendation of at least 25 total hours of nutrition instruction. While nutrition training in medical schools remains limited, claiming that only 28% have any nutrition curriculum misrepresents the data.
Following the Master Settlement Agreement, cigarette consumption in America decreased by more than half.
"and now we have the Master Settlement Agreement and we have something at least to change cigarette consumption in America, and it did go down, you know, it got cut in more than half after that." (said at 1:06:15)
While the 1998 Master Settlement Agreement (MSA) led to price increases and reductions in smoking rates and overall cigarette consumption, claiming that consumption was 'cut in more than half after that' significantly overstates the impact. Econometric evaluations of nationwide population data following the settlement found much more modest declines: by 2002, the MSA was estimated to have reduced overall smoking rates by 5% among adults aged 21 to 64, and by 13% among young adults (ages 18–20) and seniors (65+).
Short-chain fatty acids suppress the immune system and inhibit the cytokine storm caused by COVID-19, reducing mortality.
"Turns out those short-chain fatty acids are immunosuppressive and keep the cytokine storm that the virus generates at a low ebb, and so that will keep you from succumbing to massive cytokine storm from being so sick with COVID. So that will reduce mortality rates." (said at 1:08:20)
The claim is overstated. Published mechanistic and observational studies show that short-chain fatty acids (SCFAs, such as butyrate) possess immunomodulatory and anti-inflammatory properties that can dampen cytokine production and lung inflammation via the gut-lung axis. Furthermore, observational data correlate higher levels of SCFA-producing gut bacteria with milder COVID-19 severity and lower population-level mortality. However, stating definitively that SCFAs suppress the cytokine storm in COVID-19 to reduce clinical mortality overstates the evidence, as this reflects hypotheses, preclinical mechanistic models, and observational correlations rather than proven clinical trial outcomes in humans.
- partial: Human Gut Microbiota and Its Metabolites Impact Immune Responses in COVID-19 and Its Compl… (Gastroenterology 2023) · cited 151x in the literature
"Multiple correlations were found between COVID-19-related microbes (eg, oral microbes and short-chain fatty acid producers) and gut metabolites (eg, branched-chain and aromatic amino acids, short-chain fatty acids, carbohydrates, neurotransmitters, and vitamin B6). Both were also linked to inflammatory cytokine dynamics (eg, interferon γ, interferon λ3, interleukin 6, CXCL-9, and CXCL-10)." (abstract, passage verified)
pubmedfull study (doi) - partial: Lower gut abundance of Eubacterium rectale is linked to COVID-19 mortality. (Frontiers in cellular and infection microbiology 2023) · cited 12x in the literature
"We then identified the mRA of two butyrate producers, Eubacterium rectale and Roseburia intestinalis , that were negatively correlated with SMR during the study period. And the reduction of these species was associated with severer COVID-19 manifestation." (abstract, passage verified)
pubmedfull study (doi) - supports: Short-Chain Fatty Acid (SCFA) as a Connecting Link between Microbiota and Gut-Lung Axis-A … (ACS omega 2024) · cited 96x in the literature
"For instance, gut microbiota-derived metabolites such as short-chain fatty acids can suppress lung inflammation through the activation of G protein-coupled receptors (free fatty acid receptors) and can also inhibit histone deacetylase, which in turn influences the severity of acute and chronic respiratory diseases." (abstract, passage verified)
pubmedfull study (doi)
7 Needs context
Approximately 97.5% of United States healthcare spending goes to disease treatment, while only 2.5% is spent on disease prevention.
"we spend 97.5% of our healthcare dollars dealing with the treatment of diseases, much of which can be prevented. Only about 2.5% of healthcare expenditure in the United States goes to actual disease prevention." (said at 0:00:30)
The cited figure of ~2.5% for prevention and ~97.5% for treatment closely mirrors official National Health Expenditure Accounts (NHEA) data on government public health activity, which accounted for approximately 2.65% of US health expenditures in 2014 and was projected to reach ~2.4% by 2023. However, health economists note that this narrow figure reflects dedicated public health agency spending rather than total prevention. When clinical preventive services, screenings, and health promotion within clinical care are included, estimated spending on primary and secondary prevention ranges from approximately 5.1% to 8.6% of national health spending.
Fructose and alcohol are metabolized by the liver in virtually identical biochemical pathways after the initial glycolysis step.
"Well, turns out sugar, the molecule fructose, the sweet molecule in sugar, and alcohol are metabolized by the liver virtually identically... The big difference between sugar and alcohol is that for alcohol, the yeast does the first step of metabolism called glycolysis. For sugar, we do our own first step. But after that, the liver can't tell the difference as to where it came from." (said at 0:15:40)
The speaker is describing a well-known metabolic parallel popularized in the nutritional literature comparing the downstream hepatic fates of fructose and ethanol. Both bypass standard hepatic insulin-regulated checkpoints (such as phosphofructokinase for glucose), generating an unregulated influx of substrates (acetyl-CoA) that overwhelms mitochondrial capacity and promotes de novo lipogenesis, hepatic steatosis, and reactive oxygen species. However, describing their metabolism as "virtually identical" after an initial step is an oversimplification: ethanol is oxidized via alcohol dehydrogenase and aldehyde dehydrogenase into acetate and acetyl-CoA, whereas fructose is processed through fructokinase and aldolase B into three-carbon glycolytic intermediates (glyceraldehyde and dihydroxyacetone phosphate) before progressing to pyruvate, acetyl-CoA, gluconeogenesis, or glycogen synthesis.
- supports: Fructose: metabolic, hedonic, and societal parallels with ethanol. (Journal of the American Dietetic Association 2010) · cited 310x in the literature
"hepatic fructose metabolism is similar to ethanol, as they both serve as substrates for de novo lipogenesis, and in the process both promote hepatic insulin resistance, dyslipidemia, and hepatic steatosis." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Toward a unifying hypothesis of metabolic syndrome. (Pediatrics 2012) · cited 189x in the literature
"ethanol, and fructose. These 4 substrates (1) are not insulin regulated and (2) deliver metabolic intermediates to hepatic mitochondria without an appropriate "pop-off" mechanism for excess substrate, enhancing lipogenesis and ectopic adipose storage." (abstract, results, passage verified)
pubmedfull study (doi) - context: Fructose: it's "alcohol without the buzz". (Advances in nutrition (Bethesda, Md.) 2013) · cited 239x in the literature
"In the hypercaloric glycogen-replete state, intermediary metabolites from fructose metabolism overwhelm hepatic mitochondrial capacity, which promotes de novo lipogenesis and leads to hepatic insulin resistance, which drives chronic metabolic disease." (abstract, results, passage verified)
pubmedfull study (doi)
88% of adults in the United States have insulin resistance or metabolic dysfunction.
"and 88% of Americans have insulin resistance, have metabolic dysfunction because their liver is overwhelmed." (said at 0:19:15)
The 88% figure derives from a nationally representative cross-sectional study of NHANES 2009-2016 data (Araújo et al., 2019, n=8,721), which found that only 12.2% of US adults met all five criteria for optimal cardiometabolic health (optimal waist circumference, fasting glucose/HbA1c, blood pressure, triglycerides, and HDL cholesterol, without related medications). Consequently, 87.8% of adults had at least one suboptimal cardiometabolic risk factor. However, having a single non-optimal marker (such as prehypertension or elevated waist circumference) is not equivalent to having clinical insulin resistance, metabolic syndrome, or liver-driven metabolic dysfunction.
One out of every three new diabetes diagnoses in pediatric patients is type 2 diabetes.
"One out of every three new diabetes diagnoses is type 2 in kids" (said at 0:44:58)
Population surveillance from the SEARCH for Diabetes in Youth study shows that while type 1 diabetes remains the predominant form of pediatric diabetes, type 2 diabetes accounts for an increasing proportion of new diagnoses. Across the multi-center SEARCH registry (2002–2018), type 2 diabetes accounted for approximately 22.6% of new pediatric cases (5,293 of 23,462 total incident cases, or roughly 1 in 4.4). In recent years (2017–2018), type 2 diabetes incidence has risen significantly (annual incidence of 17.9 per 100,000 in youth aged 10–19 vs 22.2 per 100,000 for type 1 diabetes in youth aged 0–19), bringing the proportion of new diagnoses that are type 2 to roughly 1 in 3 to 1 in 4 across all youth, and even higher among adolescents aged 10–19 and racial/ethnic minority youth.
The reference range upper limit for alanine aminotransferase (ALT) in standard laboratory testing has shifted from 25 U/L in the 1970s up to 40 U/L today.
"I started in '76, and when I started, the upper limit for ALT was 25. Now today, if you pull out the lab slip and it just gives you the reference range, it tells you that the upper limit for ALT is 40." (said at 0:52:41)
Standard commercial laboratory reference intervals for alanine aminotransferase (ALT) have commonly reported upper limits of normal (ULN) around 40 U/L (and up to 45–55 U/L for men in many commercial assays). Epidemiological and clinical evaluations, such as the landmark study by Prati et al. (2002), demonstrated that traditional laboratory upper limits of 40 U/L for men and 30 U/L for women were established using reference populations that inadvertently included individuals with subclinical hepatic steatosis and occult viral hepatitis. When rigorously screened healthy cohorts are assessed, true physiological upper limits are lower (around 19–25 U/L in women and 30 U/L in men). While the speaker correctly notes that standard laboratory slips often report upper limits around 40 U/L despite true healthy thresholds being closer to 20–25 U/L, laboratory reference ranges vary widely by commercial assay and sex rather than reflecting a single uniform historical shift.
The average American consumes 7.5 servings of ultra-processed foods per day.
"And yet the average American is eating 7.5 servings of ultra-processed foods every day right now" (said at 1:09:32)
Dietary studies in large US prospective cohorts (such as the Nurses' Health Study and the Health Professionals Follow-up Study) and national surveys measure ultra-processed food (UPF) consumption ranging between approximately 5.7 and 7.5 servings per day (accounting for nearly 60% of daily caloric intake in the general US population). In these cohorts, 7.4 to 7.5 servings per day typically represents the upper intake categories (e.g., the highest quartile or top of the interquartile range), while the median intake is around 5.7 to 6.5 servings per day.
California requires physicians to complete 12 hours of continuing medical education (CME) in palliative care to maintain their medical license.
"In California, I had to take 12 hours of palliative care. As an endocrinologist, I had to take 12 hours of palliative care... they made me do that to keep my license, but no one says a damn thing about nutrition." (said at 1:03:32)
California law (under Business and Professions Code Section 2190.5, originally enacted via Assembly Bill 487 in 2001) mandates a one-time 12-hour continuing medical education (CME) requirement in pain management and the care of terminally ill and dying patients for licensed physicians and surgeons in California. While the speaker accurately states that physicians (including endocrinologists) practicing in California are required to complete 12 hours of CME covering palliative and end-of-life care / pain management to maintain licensure, it is a one-time requirement upon initial licensure or renewal rather than a recurring requirement for every license renewal cycle, and certain specialties (such as pathology and radiology) are exempt. Standard CME surveys across US states reflect widespread state-mandated topic-specific CME requirements for physician licensure (such as pain management and opioid prescribing), though these mandates vary by state and specialty relevancy.
No published study was located that directly addresses or verifies the speaker's comparative statement regarding nutrition education requirements relative to palliative care CME requirements in California.
20 Supported by research
The hormone leptin was discovered in 1994.
"that really started my obesity career, was the discovery of leptin in 1994." (said at 0:04:03)
The hormone leptin (the product of the obese/ob gene) was identified and cloned by Jeffrey Friedman and colleagues in 1994, a landmark discovery that established adipose tissue as an active endocrine organ regulating energy balance.
In animal studies, lesioning the hypothalamus causes hypothalamic obesity by placing the neural connection between the brain and the pancreas for insulin release into hyperdrive.
"And so lesioning the hypothalamus led to this obesity syndrome in rats called hypothalamic obesity. And what was determined was that the reason that those rats gained so much weight was because the connection between the brain and the pancreas to release insulin was in hyperdrive." (said at 0:06:35)
Classic animal experiments established that lesions to the ventromedial hypothalamus (VMH) in rodents produce rapid hyperinsulinemia and hypothalamic obesity primarily driven by parasympathetic (vagus nerve) overactivity connecting the brain to the pancreatic beta-cells. Studies demonstrated that acute post-lesion hyperinsulinemia is abolished by subdiaphragmatic vagotomy, and that transplanting denervated pancreatic tissue to the kidney capsule prevents the development of hyperinsulinemia and hypothalamic obesity after VMH lesions. Because this evidence is derived entirely from animal models, the certainty of evidence is graded as very low.
In pediatric patients with hypothalamic obesity, administering octreotide suppressed insulin release, resulting in weight loss, spontaneous physical activity, and quality-of-life improvements that correlated directly with the degree of insulin suppression.
"So in a clinical research protocol, we gave kids with this disorder this drug, octreotide, to suppress insulin. And lo and behold, not only did they lose weight—which was remarkable enough because these kids only gained weight and fast, so that was remarkable on its own—but they started exercising spontaneously... and it turned out the degree of quality of life improvement correlated with the degree of insulin suppression: the lower we got the insulin, the better these kids felt." (said at 0:07:36)
Published clinical trials led by the speaker directly support this claim. In an open-label pilot study of 8 pediatric patients with hypothalamic obesity (PMID 10431109), octreotide administration suppressed excessive insulin secretion during oral glucose tolerance testing and led to significant weight loss (-4.8 kg vs +6.0 kg pre-study). In a subsequent randomized, double-blind, placebo-controlled trial of 18 children (PMID 12788859), octreotide suppressed insulin response (P = 0.034), significantly reduced weight gain and BMI (+1.6 kg vs +9.1 kg for placebo, P < 0.001; BMI -0.2 vs +2.2 kg/m²), improved physical activity per parent report (P = 0.03), and demonstrated quality-of-life improvements that directly correlated with the degree of insulin suppression (P = 0.041). The certainty is moderate given the randomized controlled design, limited by the small sample size inherent to this rare condition.
Excess circulating insulin activates intracellular pathways leading to vascular smooth muscle proliferation, reduced cellular autophagy, and an increased risk of cancer.
"And the problem is if you have too much, you activate a whole set of other pathways in the cell, all of which lead to vascular smooth muscle proliferation, reduced autophagy, and increased risk for cancer." (said at 0:10:09)
The speaker accurately summarizes well-established physiological and molecular actions of elevated insulin signaling. Insulin stimulates vascular smooth muscle cell (VSMC) proliferation and migration primarily through the mitogen-activated protein kinase (MAPK) pathway. Concurrently, activation of the PI3K/Akt/mTOR pathway by insulin suppresses macroautophagy. Chronic hyperinsulinemia is also well recognized in epidemiological and mechanistic literature as a driver of increased risk and progression for several types of cancer through its mitogenic and anti-apoptotic signaling.
- supports: Contribution of insulin resistance to vascular dysfunction. (Archives of physiology and biochemistry 2009) · cited 50x in the literature
"We also discuss the insulin actions mediated by the MAPK pathway (such as endothelin-1 synthesis and secretion and VSMC proliferation and migration) and by the interactions between the two pathways, both in insulin-sensitive and in insulin-resistant states." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Overnutrition, mTOR signaling, and cardiovascular diseases. (American journal of physiology. Regulatory, integrative and comparative physiology 2014) · cited 124x in the literature
"There is emerging evidence that excessive nutrient intake promotes signaling through the mammalian target of rapamycin (mTOR), which, in turn, may lead to alterations of cellular metabolic signaling leading to insulin resistance and obesity-related diseases, such as diabetes, cardiovascular and kidney disease, as well as cancer." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Diabetes and cancer, common threads and missing links. (Cancer letters 2016) · cited 86x in the literature
"Several pathophysiological mechanisms for this relationship have been postulated, including insulin resistance and hyperinsulinemia, enhanced inflammation, aberrant metabolic state, endoplasmic reticulum stress, and deregulation of autophagy." (abstract, results, passage verified)
pubmedfull study (doi)
The insulin receptor is coupled to the mitogen-activated protein kinase (MAP kinase) pathway, which stimulates cell growth and division.
"There is—the insulin receptor is coupled to a pathway in the cell that basically makes cells grow and divide. It's called MAP kinase, mitogen-activated protein kinase, and that pathway is very important when you are growing, like for instance a fetus." (said at 0:11:11)
The speaker accurately described the canonical signaling pathway downstream of the insulin receptor. Insulin binding leads to phosphorylation of insulin receptor substrates (such as IRS-1), which couples to the mitogen-activated protein kinase (MAPK/ERK) cascade to stimulate cellular growth, division, and mitogenesis. This signaling mechanism plays a key role in cellular proliferation and developmental processes, including fetal growth.
- supports: Intrauterine growth restriction in humans is associated with abnormalities in placental in… (Endocrinology 2005) · cited 152x in the literature
"The IGFs promote the growth and development of the feto-placental unit during gestation, and impairment of their placental actions may result in altered intrauterine growth of the fetus." (abstract, background, passage verified)
pubmedfull study (doi) - supports: Differential mitogenic signaling in insulin receptor-deficient fetal pancreatic beta-cells… (Endocrinology 2006) · cited 27x in the literature
"In beta-IRLoxP beta-cells, p44/p42 MAPK and phosphatidylinositol 3 kinase pathways, mammalian target of rapamycin (mTOR), and p70S(6)K phosphorylation and beta-cell proliferation were stimulated in response to insulin." (abstract, results, passage verified)
pubmedfull study (doi) - supports: miR-203 inhibits cell proliferation and ERK pathway in prostate cancer by targeting IRS-1. (BMC cancer 2020) · cited 29x in the literature
"Importantly, miR-203 overexpression blocks ERK signalling pathway by down-regulating IRS-1 expression." (abstract, results, passage verified)
pubmedfull study (doi)
Fructose is phosphorylated to fructose-1-phosphate in the liver, depleting ATP to ADP and AMP, which is subsequently converted into uric acid.
"So first of all, fructose is phosphorylated in the liver to fructose-1-phosphate. That reduces ATP to ADP, and then that goes to AMP, that goes to uric acid. And that's the reason why sugar causes gout, is because it raises uric acid." (said at 0:22:56)
The biochemical mechanism described by the speaker is well established in metabolic research. In the liver, fructose is rapidly phosphorylated to fructose-1-phosphate by fructokinase (ketohexokinase). Unlike glucose phosphorylation, this step is not tightly regulated by intracellular energy status, leading to transient depletion of intracellular adenosine triphosphate (ATP) and accumulation of adenosine diphosphate (ADP) and adenosine monophosphate (AMP). The excess AMP enters the purine catabolic pathway, resulting in increased production and systemic accumulation of uric acid, which directly links high fructose and sugar intake to hyperuricemia and gout.
- supports: Uric acid stimulates fructokinase and accelerates fructose metabolism in the development o… (PloS one 2012) · cited 285x in the literature
"The first step in fructose metabolism is mediated by fructokinase (KHK), which phosphorylates fructose to fructose-1-phosphate; intracellular uric acid is also generated as a consequence of the transient ATP depletion that occurs during this reaction." (abstract, background, passage verified)
pubmedfull study (doi) - supports: Sugar, uric acid, and the etiology of diabetes and obesity. (Diabetes 2013) · cited 760x in the literature
"Fructose is a major component of added sugars and is distinct from other sugars in its ability to cause intracellular ATP depletion, nucleotide turnover, and the generation of uric acid." (abstract, background, passage verified)
pubmedfull study (doi) - supports: The Impact of Fructose Consumption on Human Health: Effects on Obesity, Hyperglycemia, Dia… (Cureus 2024) · cited 18x in the literature
"Furthermore, fructose-induced adenosine triphosphate depletion activates purine degradation, increasing uric acid levels and exacerbating hyperuricemia." (abstract, results, passage verified)
pubmedfull study (doi)
A 2019 study led by Softic and C. Ronald Kahn showed that glucose stimulates mitochondrial fatty acid oxidation via AMP kinase and hydroxyacyl-CoA dehydrogenase (HADH), whereas fructose inhibits AMP kinase and long-chain acyl-CoA dehydrogenase (ACADL).
"Ron Kahn, the head of the—CEO of Joslin Diabetes Center at Harvard—published a paper, the first author was Softic, S-O-F-T-I-C, in 2019 where he showed that glucose stimulates mitochondrial function through activation of both AMP kinase and HADH, which is hydroxyacyl-CoA dehydrogenase, which is the third step on fatty acid oxidation... Fructose, not only does it inhibit AMP kinase, but it also inhibits another enzyme called ACADL, acyl-CoA dehydrogenase long-chain. And so what happens is the fats build up, and so now you got fatty liver." (said at 0:23:36)
A 2019 mouse study by Softic et al. and C. Ronald Kahn published in Cell Metabolism demonstrated that dietary fructose and glucose exert divergent effects on hepatic mitochondrial function and fatty acid oxidation. Fructose supplementation on a high-fat diet impaired fatty acid oxidation through mechanisms including acetylation and reduced activity of long-chain acyl-CoA dehydrogenase (ACADL) and CPT1a, while glucose supplementation did not impair mitochondrial fat oxidation. Because these findings are derived from preclinical rodent models, the GRADE certainty regarding direct human clinical outcomes is very low, but the speaker's summary accurately reflects the published study's findings and mechanisms.
- supports: Dietary Sugars Alter Hepatic Fatty Acid Oxidation via Transcriptional and Post-translation… (Cell metabolism 2019) · cited 232x in the literature
"Furthermore, fructose-supplemented HFD leads to increased acetylation of ACADL and CPT1a, which is associated with decreased fat metabolism. In summary, dietary fructose, but not glucose, supplementation of HFD impairs mitochondrial size, function, and protein acetylation, resulting in decreased fatty acid oxidation and development of metabolic dysregulation." (abstract, results, passage verified)
pubmedfull study (doi)
Beta-hydroxybutyrate functions as a signaling molecule that activates sirtuins, stimulating mitochondrial oxidative burning.
"and you're also getting the benefit of the beta-hydroxybutyrate, which is in itself a signaling molecule. It signals sirtuins, which signal mitochondrial function, which signal burning, which is good." (said at 0:28:32)
Preclinical evidence demonstrates that beta-hydroxybutyrate (BHB) acts as a signaling metabolite that upregulates and activates sirtuin enzymes (such as SIRT1 and SIRT3). Activation of these mitochondrial and nuclear sirtuins downstream promotes mitochondrial biogenesis, enhances mitochondrial membrane potential, and stimulates mitochondrial oxidative respiration and metabolic function.
- supports: Neuroketotherapeutics: A modern review of a century-old therapy. (Neurochemistry international 2018) · cited 144x in the literature
"Data indicate ketotherapeutics enhance mitochondrial respiration, promote neuronal long-term potentiation, increase BDNF expression, increase GPR signaling, attenuate oxidative stress, reduce inflammation, and alter protein post-translational modifications via lysine acetylation and β-hydroxybutyrylation. These properties have further downstream implications involving Akt, PLCγ, CREB, Sirtuin, and mTORC pathways." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Preconditioning with β-hydroxybutyrate attenuates lung ischemia-reperfusion injury by supp… (FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2024) · cited 9x in the literature
"This revealed that β-OHB exerts lung-protective and anti-pyroptotic effects, which were mediated through the upregulation of SIRT1 and the enhancement of FOXO3 deacetylation..." (abstract, results)
pubmedfull study (doi) - supports: SIRT3 is required for the protective function of ketogenic diet on neural inflammation and… (International journal of biological sciences 2025) · cited 4x in the literature
"Both in vivo and in vitro experiments revealed KD-induced upregulation of uncoupling protein 2 (UCP2), sirtuin 3 (SIRT3) and peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1α) in the spinal dorsal horn." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Comparison of Antioxidant Effects of 3-Hydroxybutyrate and Sodium 3-Hydroxybutyrate Throug… (Journal of biochemical and molecular toxicology 2025)
"3HBH exhibited a stronger ability to activate the sirtuin 3 (SIRT3)/forkhead box O3 (FOXO3A) pathway." (abstract, results, passage verified)
pubmedfull study (doi)
Wheat is a hexaploid organism rather than a diploid organism.
"Turns out wheat is a very complex organism. It's a hexaploid, not diploid, and there" (said at 0:29:40)
Common bread wheat (Triticum aestivum) is an allohexaploid organism (2n = 6x = 42 chromosomes) composed of three distinct subgenomes (A, B, and D), rather than a diploid organism (which possesses only two sets of chromosomes). It arose through natural hybridization between a tetraploid wheat progenitor (AABB) and the diploid wild grass Aegilops tauschii (DD).
The diabetes drug metformin acts to stimulate AMP kinase.
"The drug metformin, which is given—used for diabetes—acts to stimulate this AMP kinase." (said at 0:25:28)
Metformin is a standard first-line medication for type 2 diabetes mellitus. Extensive pharmacological and biochemical research confirms that metformin stimulates/activates AMP-activated protein kinase (AMPK), primarily secondary to its mild inhibition of mitochondrial complex I, which alters cellular energy charge (increasing AMP/ATP ratios). While research indicates metformin also exerts some AMPK-independent metabolic effects, stimulation of AMPK is a well-established component of its molecular mechanism.
- supports: Metformin--mode of action and clinical implications for diabetes and cancer. (Nature reviews. Endocrinology 2014) · cited 1380x in the literature
"Stimulation of 5'-AMP-activated protein kinase, although dispensable for the glucose-lowering effect of metformin, confers insulin sensitivity, mainly by modulating lipid metabolism." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. (Nature reviews. Endocrinology 2019) · cited 688x in the literature
"In addition, the discovery that metformin inhibits the mitochondrial respiratory chain complex 1 has placed energy metabolism and activation of AMP-activated protein kinase (AMPK) at the centre of its proposed mechanism of action." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Metformin as a potential therapeutic for neurological disease: mobilizing AMPK to repair t… (Expert review of neurotherapeutics 2021) · cited 110x in the literature
"The mechanism of action of metformin involves activation of AMP-activated protein kinase (AMPK) to enhance mitochondrial function (for example, biogenesis, refurbishment and dynamics) and autophagy." (abstract, introduction, passage verified)
pubmedfull study (doi)
Starving gut bacteria causes them to consume the intestinal epithelial mucin layer, reducing tight junction integrity and allowing lipopolysaccharides and bacteria to enter the bloodstream.
"And if you eat that mucin layer off your intestinal epithelial cells, now the bacteria are opposed right on your intestinal epithelial cells, and that has been shown to reduce the integrity of the tight junctions that basically keep your intestinal barrier. And so now you've got lipopolysaccharides and cytokines and bacteria themselves making their way through to your bloodstream" (said at 0:37:48)
The speaker accurately describes a mechanism demonstrated in gnotobiotic and murine models. Landmark research showed that when gut microbiota are deprived of dietary fiber, commensal bacteria switch to utilizing host-secreted mucin glycoproteins as an energy source. This degrades the protective colonic mucus layer, places bacteria in direct contact with the intestinal epithelium, disrupts mucosal barrier integrity, and facilitates bacterial translocation and inflammation. Because the complete causal chain is demonstrated primarily in animal models, the certainty of evidence for humans is very low.
- supports: A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pa… (Cell 2016) · cited 2899x in the literature
"We show that during chronic or intermittent dietary fiber deficiency, the gut microbiota resorts to host-secreted mucus glycoproteins as a nutrient source, leading to erosion of the colonic mucus barrier. Dietary fiber deprivation, together with a fiber-deprived, mucus-eroding microbiota, promotes greater epithelial access and lethal colitis by the mucosal pathogen, Citrobacter rodentium." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Deprivation of dietary fiber in specific-pathogen-free mice promotes susceptibility to the… (Gut microbes 2021) · cited 83x in the literature
"We show that absence of dietary fiber intake leads to shifts in the abundances of specific taxa, microbiome-mediated erosion of the colonic mucus barrier, a reduction of intestinal barrier-promoting short-chain fatty acids, and increases in markers of mucosal barrier integrity disruption." (abstract, results, passage verified)
pubmedfull study (doi)
Colonic bacteria ferment soluble fiber into short-chain fatty acids, specifically propionate and butyrate, which exert anti-inflammatory and insulin-sensitizing effects.
"The colonic bacteria love soluble fiber, and they do you a favor because not only do they chew it up, but the waste product of their chewing up that fiber is short-chain fatty acids, propionate and butyrate, which turn out to be anti-inflammatory and anti-insulin for you." (said at 0:39:11)
Colonic bacterial fermentation of soluble dietary fiber produces short-chain fatty acids (SCFAs), principally acetate, propionate, and butyrate. A substantial body of preclinical research and human interventional trials demonstrates that these metabolites promote anti-inflammatory pathways, support intestinal barrier integrity, and improve insulin sensitivity and glycemic control.
- supports: Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. (Cell 2014) · cited 2210x in the literature
"Here, we show that the short-chain fatty acids (SCFAs) propionate and butyrate, which are generated by fermentation of soluble fiber by the gut microbiota, activate IGN via complementary mechanisms." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Fecal Short-Chain Fatty Acids (SCFAs) and Their Role in Metabolic Disorders: A Systematic … (Cureus 2025) · cited 7x in the literature
"Fecal short-chain fatty acids (SCFAs), such as acetate, propionate, and butyrate, are gut microbial metabolites that influence energy balance, glucose regulation, lipid metabolism, and inflammation... targeted SCFA supplementation, particularly with propionate or butyrate, improved insulin sensitivity and reduced energy intake." (abstract, results)
pubmedfull study (doi) - supports: Gut Microbiota and Metabolic Syndrome: A Narrative Review. (Biology 2026)
"Bacterial fermentation of dietary fiber produces short-chain fatty acids (SCFAs), including butyrate, acetate, and propionate, which contribute to intestinal barrier integrity, inflammatory regulation, immune regulation, and metabolic homeostasis." (abstract, results, passage verified)
pubmedfull study (doi)
Chronic non-communicable degenerative diseases are the number one cause of death globally according to the World Health Organization.
"these chronic degenerative conditions are, according to the World Health Organization, the number one cause of death on the planet." (said at 0:41:11)
Epidemiological data from the World Health Organization and global health surveillance establish that non-communicable diseases (NCDs)—including cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes—are the leading cause of death globally, accounting for nearly three-quarters of all deaths worldwide.
Prohormone convertase 1 is the enzyme responsible for cleaving C-peptide from the proinsulin molecule to form mature insulin.
"prohormone convertase 1, which is the enzyme that cleaves the C-peptide out of the proinsulin molecule to make a mature, functional insulin." (said at 0:47:47)
Prohormone convertase 1 (also known as PC1 or PC1/3, encoded by PCSK1) is the primary endoprotease responsible for endoproteolytic cleavage of proinsulin to excise C-peptide and yield mature insulin. While classical models in rodents involved both PC1/3 and PC2 followed by carboxypeptidase E trimming, human beta-cell studies demonstrate that PC1/3 is the primary convertase required for proinsulin processing to mature insulin.
- supports: Islet prohormone processing in health and disease. (Diabetes, obesity & metabolism 2018) · cited 86x in the literature
"Like neuroendocrine peptides, insulin and other islet hormones are first synthesized as larger precursor molecules that are processed to their mature secreted products through a series of proteolytic cleavages, mediated by the prohormone convertases Pc1/3 and Pc2, and carboxypeptidase E." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Revisiting Proinsulin Processing: Evidence That Human β-Cells Process Proinsulin With Proh… (Diabetes 2020) · cited 52x in the literature
"Conversely, suppression of PC1/3 blocked processing of proinsulin but not proglucagon. By demonstrating that healthy human β-cells process proinsulin by PC1/3 but not PC2, we suggest that there is a need to revise the long-standing theory of proinsulin processing." (abstract, results, passage verified)
pubmedfull study (doi)
Hepatic fructose metabolism consumes ATP without a phosphate-scavenging pathway to return it, driving conversion of AMP into uric acid.
"when fructose enters the liver, ATP has to donate a phosphate. So ATP becomes ADP, and then it goes into AMP into uric acid. There's no scavenger mechanism to return that, so it goes to uric acid." (said at 0:54:43)
Published biochemical and clinical research confirms that hepatic fructose metabolism is initiated by ketohexokinase (fructokinase), which rapidly phosphorylates fructose to fructose-1-phosphate using ATP. Because ketohexokinase lacks negative feedback control and traps phosphate in fructose-1-phosphate, rapid ATP depletion occurs alongside intracellular phosphate depletion. This triggers adenylate kinase (converting ADP to AMP) and activates AMP deaminase (normally inhibited by inorganic phosphate), driving purine nucleotide degradation of AMP down the catabolic pathway into uric acid.
Uric acid is an endogenous inhibitor of endothelial nitric oxide synthase (eNOS), which contributes to elevated blood pressure.
"uric acid is the endogenous inhibitor of the enzyme in your blood vessels, endothelial nitric oxide synthase, or eNOS, which is your endogenous blood pressure lowerer. And so when your uric acid is high, your blood pressure goes up" (said at 0:55:17)
Preclinical in vitro and animal studies demonstrate that elevated uric acid directly impairs endothelial nitric oxide synthase (eNOS) phosphorylation and activity via the Akt pathway, reducing nitric oxide (NO) bioavailability and contributing to endothelial dysfunction and elevated blood pressure. In animal models, hyperuricemia raises arterial blood pressure, an effect reversible by lowering uric acid (e.g., with allopurinol) or enhancing the nitric oxide pathway (such as with L-arginine). Observational human studies also correlate higher serum uric acid with impaired endothelial function.
Insulin promotes the reabsorption of sodium at the level of the kidney.
"Insulin helps resorb sodium, and so in the face of a high insulin, that 6.9 grams ends up being enormous." (said at 0:56:30)
The claim is supported. Insulin acts directly on multiple segments of the renal tubule (including the proximal tubule and collecting duct via channels such as ENaC) to facilitate renal sodium reabsorption, acutely decreasing urinary sodium excretion independently of the renin-angiotensin-aldosterone system.
Primate ancestors developed uricase gene mutations 14 to 18 million years ago that resulted in elevated uric acid levels.
"Dr. Richard Johnson characterized as being a survival mechanism for our primate ancestors 14 to 18 million years ago when we developed the mutation—the uricase mutation, actually there were several—that led to humans, our ancestors rather, having higher levels of uric acid" (said at 0:58:11)
Evolutionary genomic and biochemical studies led by Dr. Richard Johnson and colleagues confirm that ancestral hominoids underwent pseudogenizing mutations in the urate oxidase (uricase) gene during the mid-Miocene epoch (approximately 14 to 18 million years ago). These mutations led to the loss of functional uricase, resulting in higher circulating uric acid levels. Published work demonstrates that higher uric acid functioned as an evolutionary survival mechanism to stimulate fat accumulation, support gluconeogenesis, and maintain blood pressure during periods of global cooling and nutritional famine.
- supports: Theodore E. Woodward award. The evolution of obesity: insights from the mid-Miocene. (Transactions of the American Clinical and Climatological Association 2010) · cited 46x in the literature
"humans have higher serum uric acid levels due to a mutation in uricase that occurred in the mid Miocene. In this paper we review the hypothesis that these mutations have in common the induction of oxidative stress that may have had prosurvival effects to enhance the effects of fructose to increase fat stores." (abstract, results, passage verified)
pubmed - supports: Uric acid-dependent inhibition of AMP kinase induces hepatic glucose production in diabete… (FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2014) · cited 187x in the literature
"In this regard, humans have higher uric acid levels than most mammals due to a mutation in uricase, the enzyme involved in uric acid degradation in most mammals, that developed during a period of famine in Europe 1.5 × 10(7) yr ago. Here, working with resurrected ancestral uricases obtained from early hominids, we show that their expression on HepG2 cells is enough to blunt gluconeogenesis in parallel with an up-regulation of AMPK activity." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Fructose metabolism as a common evolutionary pathway of survival associated with climate c… (Journal of internal medicine 2020) · cited 130x in the literature
"Twice in history, mutations occurred during periods of mass extinction that enhanced the activity of fructose to generate fat, with the first being a mutation in vitamin C metabolism during the Cretaceous-Paleogene extinction (65 million years ago) and the second being a mutation in uricase that occurred during the Middle Miocene disruption (12-14 million years ago)." (abstract, results, passage verified)
pubmedfull study (doi)
SARS-CoV-2 uses ACE2 as its entry point to infect cells.
"Because that COVID virus is so freaking goddamn smart, it uses ACE2 as its entry point. And so the more molecules of ACE2 you have on the surface of your cell, the more chance that that virus is going to infect you." (said at 1:07:55)
Extensive in vitro and molecular studies established early in the COVID-19 pandemic that SARS-CoV-2 utilizes angiotensin-converting enzyme 2 (ACE2) as its primary functional host cell entry receptor. Binding of the viral spike glycoprotein to cell-surface ACE2 enables viral attachment and subsequent host cell entry (often facilitated by host proteases such as TMPRSS2).
Studies at UCSF showed that eating real food reduces insulin, fatty liver, uric acid, and ALT in nine days.
"We have shown in our studies at UCSF that you can get your insulin down, and you can get your fatty liver down, and you can get your uric acid and your ALT down in nine days—nine days—by eating real food." (said at 1:09:00)
Studies conducted by Dr. Robert Lustig and colleagues at UCSF (such as the 2016 Obesity trial and 2017 Gastroenterology publication) tested a 9-day dietary intervention in children with obesity and metabolic syndrome. In these studies, dietary sugar/fructose was restricted and substituted isocalorically with starch. The trials demonstrated rapid, statistically significant reductions in hyperinsulinemia and insulin kinetics, liver fat (hepatic steatosis measured via magnetic resonance spectroscopy decreased from a median of 7.2% to 3.8%), visceral fat, and circulating metabolic biomarkers over the 9-day period. Describing this intervention as 'eating real food' refers to the study's design of removing processed/added sugars from the children's diets.
- supports: Isocaloric fructose restriction and metabolic improvement in children with obesity and met… (Obesity (Silver Spring, Md.) 2016) · cited 190x in the literature
"Participants consumed a diet for 9 days to deliver comparable percentages of protein, fat, and carbohydrate as their self-reported diet; however, dietary sugar was reduced from 28% to 10% and substituted with starch... Glucose tolerance and hyperinsulinemia improved (P < 0.001)." (abstract, methods and results, passage verified)
pubmedfull study (doi) - supports: Effects of Dietary Fructose Restriction on Liver Fat, De Novo Lipogenesis, and Insulin Kin… (Gastroenterology 2017) · cited 264x in the literature
"Short-term (9 days) isocaloric fructose restriction decreased liver fat, VAT, and DNL, and improved insulin kinetics in children with obesity." (abstract, conclusions, passage verified)
pubmedfull study (doi)
8 No source found (not proven false)
Non-alcoholic fatty liver disease affects 45% of American adults.
"It is 45% of American adults and 25% of American children today, having nothing to do with obesity." (said at 0:18:50)
No published record matching the claim that non-alcoholic fatty liver disease affects 45% of American adults was located; this does not prove the claim false.
Dr. Lustig treated two pediatric patients weighing over 400 pounds who developed cirrhosis requiring liver transplants caused purely by drinking sugary beverages.
"You mentioned in your book that you had two pediatric patients, each of whom weighed in excess of 400 pounds, who developed actual cirrhosis. And did they need transplant? Right. And I think you said just from drinking sugary beverages. GUEST: That's right, just from drinking sugary beverages." (said at 0:18:20)
No published record matching the clinical account of two pediatric patients weighing over 400 pounds who developed cirrhosis requiring liver transplants solely from sugary beverage consumption was located; this does not prove the claim false.
Twelve percent of American adults have five chronic diseases.
"You indicated that 12% of adults in America don't have one, two, three, four—have five. 12% of American adults have five chronic diseases." (said at 0:43:58)
No published record matching the claim that 12% of American adults have five chronic diseases was located; this does not prove the claim false.
Uric acid interferes with the mitochondrial enzyme carnitine palmitoyltransferase 1 (CPT-1).
"It has effects on the mitochondria because it interferes with the enzyme carnitine palmitoyltransferase 1, so it means that you're not getting stuff into your mitochondria to be able to get things burned." (said at 0:55:07)
No published record matching the claim that uric acid interferes with carnitine palmitoyltransferase 1 (CPT-1) was located; this does not prove the claim false.
Average salt intake prior to refrigeration was approximately 15 grams per day without widespread hypertension, compared to modern intake of 6.9 grams per day with a 40% incidence of hypertension.
"The average consumption of salt prior to refrigeration was about 15 grams of salt per day—15—and there was no hypertension. But today the average consumption of salt is 6.9 grams per day—half as much—and we have a 40% incidence of hypertension." (said at 0:56:05)
No published record matching the claim that average salt consumption prior to refrigeration was 15 grams per day without hypertension, compared to modern intake of 6.9 grams per day with a 40% incidence of hypertension, was located; this does not prove the claim false. Published evolutionary and historical reviews note that human populations evolved in low-salt environments and that dietary salt intake has markedly increased in recent decades alongside rising hypertension rates.
Wheat contains approximately 700 different antigens, of which gliadin and glutenin are two.
"are 700 different antigens. Two of them are gluten, so gliadin and glutenin, and those are the famous ones and those are the ones we have tests for. The other 698 we don't have tests for" (said at 0:30:02)
No published record matching the claim that wheat contains approximately 700 distinct antigens, with tests existing for only two (gliadin and glutenin) and 698 remaining untestable, was located; this does not prove the claim false. Proteomic and allergenomic studies show that wheat contains a diverse and complex array of both gluten (gliadins, glutenins) and non-gluten proteins (such as alpha-amylase/trypsin inhibitors, serpins, and agglutinins) capable of triggering immune responses. However, the specific quantification of 700 discrete antigens and the binary division regarding test availability are not substantiated in the peer-reviewed scientific literature.
Neither Abraham Flexner nor Simon Flexner believed in nutrition, which led to nutrition not being taught in medical schools following the Flexner Report.
"And to be honest with you, that goes back 110 years to the Flexner Report, because neither Flexner, Abraham nor Simon, believed in nutrition." (said at 1:00:26)
No published record matching the claim that neither Abraham Flexner nor Simon Flexner believed in nutrition, or that their personal disbelief in nutrition led to its exclusion from medical school curricula following the Flexner Report, was located; this does not prove the claim false.
no web source foundNo reliable historical sources or biographies record that Abraham Flexner or Simon Flexner personally disbelieved in nutrition. While the 1910 Flexner Report restructured medical education around the biomedical model and laboratory sciences, there is no documentation that a personal disbelief in nutrition influenced medical curricula.
nih.govpsychologytoday.com
Insulin drives the production of ACE2 on the cell surface.
"Insulin: turns out insulin drives ACE2—ACE2, angiotensin-converting enzyme 2. Now, that is normally a water channel in cells, especially lung, but it drives the production of ACE2." (said at 1:07:37)
No published record matching the claim that insulin drives the production of ACE2 on the cell surface was located; this does not prove the claim false. In addition, angiotensin-converting enzyme 2 (ACE2) functions physiologically as a membrane-bound carboxypeptidase within the renin-angiotensin system—converting angiotensin II into angiotensin-(1-7)—rather than serving as a cellular water channel (a role performed by aquaporins).
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.